This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Il Dong Pharmaceutical Co., Ltd.. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Dami Lim - Innovator in CFTR Modulation
Introduction
Dami Lim is a notable inventor based in Hwaseong, South Korea. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that modulate the cystic fibrosis transmembrane conductance regulator (CFTR). Her innovative work has the potential to impact treatments for various diseases.
Latest Patents
Dami Lim holds a patent for "Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators." This patent provides CFTR modulator and phosphodiesterase 4 (PDE4) inhibitor compounds, which can be utilized for modulating CFTR functionality. The compounds are designed for treating eye diseases or disorders and CFTR-related indications. Additionally, the patent outlines methods for using these compounds to inhibit PDE4 in biological systems, addressing inflammatory diseases and other PDE4-related conditions.
Career Highlights
Throughout her career, Dami Lim has demonstrated a commitment to advancing medical science through her research and innovations. Her work at Il Dong Pharmaceutical Co., Ltd. has positioned her as a key player in the pharmaceutical industry.
Collaborations
Dami Lim has collaborated with esteemed colleagues, including Te-ik Sohn and Jungho Kim, to further her research and development efforts.
Conclusion
Dami Lim's contributions to CFTR modulation and her innovative patent highlight her role as a leading inventor in the pharmaceutical field. Her work continues to pave the way for advancements in treatment options for various diseases.